Absci Corporation
General ticker "ABSI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $382.2M (TTM average)
Absci Corporation follows the US Stock Market performance with the rate: 29.2%.
Estimated limits based on current volatility of 4.8%: low 3.19$, high 3.51$
Factors to consider:
- Total employees count: 157 (+0.6%) as of 2024
- Top business risk factors: Limited operating history, Risk management effectiveness, IT system disruptions, Geopolitical risks, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.71$, 4.17$]
- 2025-12-31 to 2026-12-31 estimated range: [1.37$, 3.39$]
Financial Metrics affecting the ABSI estimates:
- Positive: with PPE of -3.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -22.81 <= 0.33
- Negative: negative Net income
- Positive: -14.38 < Investing cash flow per share per price, % of -13.10
- Positive: Shareholder equity ratio, % of 83.86 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.18 <= 0.79
Short-term ABSI quotes
Long-term ABSI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $5.75MM | $5.72MM | $4.53MM |
| Operating Expenses | $112.50MM | $121.23MM | $113.42MM |
| Operating Income | $-106.75MM | $-115.52MM | $-108.89MM |
| Non-Operating Income | $1.39MM | $5.05MM | $5.85MM |
| Interest Expense | $0.97MM | $1.01MM | $0.56MM |
| R&D Expense | $58.91MM | $48.07MM | $63.86MM |
| Income(Loss) | $-105.36MM | $-110.47MM | $-103.04MM |
| Taxes | $-0.46MM | $0.10MM | $0.07MM |
| Profit(Loss)* | $-104.90MM | $-110.57MM | $-103.11MM |
| Stockholders Equity | $274.41MM | $176.18MM | $179.13MM |
| Inventory | $15.02MM | $0.00MM | $0.00MM |
| Assets | $321.01MM | $217.30MM | $213.61MM |
| Operating Cash Flow | $-81.34MM | $-64.64MM | $-72.40MM |
| Capital expenditure | $16.18MM | $0.86MM | $0.40MM |
| Investing Cash Flow | $-126.98MM | $81.94MM | $-41.58MM |
| Financing Cash Flow | $5.24MM | $-4.48MM | $82.53MM |
| Earnings Per Share** | $-1.15 | $-1.20 | $-0.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.